RxDoctor Payments Data

Lesly Silva, MD

Internal Medicine · Naples, FLNPI 1700316379

Payments from drug & device makers

$476in general payments, 2019–2025

Across 15 payments — averaging $31.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$221
  • Esperion Therapeutics, Inc.$103
  • Novartis$39
  • Coaptech, Inc.$31
  • CSL Behring$25
  • E.r. Squibb & Sons, L.L.C.$21
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$476 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$274,860
Medicare patients
249
Services billed
2,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$23,546
FarxigaDapagliflozin Propanediol19$10,623
EntrestoSacubitril/Valsartan14$8,859
Humalog Kwikpen U-100Insulin Lispro15$1,773
Pantoprazole Sodium44$1,752
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$1,558
Levetiracetam24$718
Insulin Lispro Kwikpen U-100Insulin Lispro16$715
Nifedipine ErNifedipine26$706
Atorvastatin Calcium43$660
Hydralazine Hcl29$464
Donepezil Hcl28$445
Rosuvastatin Calcium51$420
ClopidogrelClopidogrel Bisulfate32$420
Sertraline Hcl20$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$39$8,85914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →